Patient demographic information (gender and weight), previous co-morbidities (previous cerebrovascular disease, diabetes, cardiovascular disease, pulmonary disease, renal disease, and/or liver disease), tumor characteristics (multi-site brain tumor), and laboratory tests (PLT, activated APTT, fibrinogen, D-dimer, TP, and ALB were not different between the transfused and non-transfused groups (P > 0.05). This evidence concerns the gene ALB and kidney disorder.